Covid-19
Conditions
Keywords
Blood samples, ADN, ARN, plasma
Brief summary
Biological collection (blood sample) associated with clinical data from Covid-19 patients
Detailed description
SARS-Cov2 is an emerging respiratory virus in the coronavirus family, responsible of the pandemic since November 2019. France, which has more than 17,000 deaths from the virus, is one of the main outbreaks. As of 16 April 2020, more than 76,000 individuals in France have been hospitalized, corresponding to 69% of confirmed cases (https://www.santepubliquefrance.fr). Most affected patients have more or less marked clinical signs associating fever, cough, dyspnea, myalgia, anosmia, ageusia, digestive disorders. In some cases, the progression is worse with lung disease of varying severity. Indications for hospitalization are essentially the severe forms of Covid-19 disease, characterized by hypoxemic lung disease. Risk factors for developing severe Covid-19 disease have been identified already: age, co-morbidity such as diabetes, obesity-overweight or cardiovascular diseases. It is assumed that other host-related factors, including genetics, may contribute to the existence of this phenotypic heterogeneity. At present, these factors are not known. The objective of this research is to constitute a DNA collection from patients with Covid-19, in order to be able to search for genetic factors modulating the clinical phenotype.
Interventions
BIOLOGICALBiological test
Blood sample
Sponsors
Centre Hospitalier Intercommunal Creteil
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Collection of blood samples in a cohort of Covid-19 patients
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Diagnosis of COVID-19 confirmed on RT-PCR test or chest scanner * Any age * Membership in the general social security system * Inform consent signed by the patient or by legal representatives for minors
Exclusion criteria
* Refusal of the patient or one of the legal representatives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phenotype/genotype correlation research modulating the severity of Covid-19 disease | Anytime in the period of 10 years | Clinical aggravation markers (admission in intensive care) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phenotype/biomarker correlation research modulating the severity of Covid-19 disease | Anytime in the period of 10 years | Severity at the Covid-19 Lung Scanner |
| Development of clinical-biological scores in the severity of Covid-19 disease | Anytime in the period of 10 years | Evolution of scanographic lesions or pulmonary ultrasound |
| Development of predictive imaging scores in the severity of Covid-19 disease | Anytime in the period of 10 years | Evolution of scanographic lesions or pulmonary ultrasound |
| Phenotype/transcriptomic correlation research modulating the severity of Covid-19 disease | Anytime in the period of 10 years | Severity at the Covid-19 Lung Scanner |
| Identification of genetic markers for treatment response | Anytime in the period of 10 years | Genome sequencing |
| Identification of transcriptomic markers for treatment response | Anytime in the period of 10 years | Sequencing transcriptome |
| Identification of proteomic for treatment response | Anytime in the period of 10 years | Proteomic sequencing |
| Identification of pathophysiological pathways to susceptibility to Covid-19 disease | Anytime in the period of 10 years | Duration of oxygen therapy, artificial ventilation |
Countries
France
Outcome results
None listed